”One of four technologies innovating mental health.”
-Forbes

$2M+ RAISED | 1000+ INVESTORS

Invest in Fisher Wallace

About our Equity Crowdfunding Campaign

Fisher Wallace Laboratories, a leading medical device startup for the treatment of anxiety, depression and insomnia, is raising capital for R&D and to scale its non-drug treatment solution. This campaign is regulated by the Securities & Exchange Commission (SEC) and managed by StartEngine, a leading equity crowdfunding platform. Investors may receive a free Fisher Wallace Stimulator®. Learn more.

We are an established enterprise

Cleared by the FDA. Over 60,000 patients and 10,000 prescribers. More than $23.3M in lifetime revenue and over $3M raised via equity crowdfunding to date. 

We are backed by clinical research

Three clinical trials submitted to FDA on March 19th of this year to obtain approval for one or more indications.


We address an enormous clinical need

According to the CDC, rates of depression and anxiety have skyrocketed during the pandemic. Our safe, effective solution is rapidly FedExed directly to the patient's home following a telemedicine prescription.


Multiple paths to liquidity

Fisher Wallace has signed an agreement with StartEngine to participate in StartEngine Secondary, a new investor trading platform that will match orders for buyers and sellers of Fisher Wallace securities. Fisher Wallace will not join this platform until after its closes its current equity crowdfunding campaign. Listing on StartEngine Secondary provides shareholders access to a marketplace for their shares.


10K+

Prescribers in the U.S.

< 1%

Side Effect Rate

$23M+

Lifetime Revenue

Investors may receive a free Fisher Wallace Stimulator®. Learn more.

Product FAQ

How does the device work?

The Fisher Wallace Stimulator® works by stimulating the brain to produce neurochemicals such as serotonin, while modulating the default mode network and entraining alpha waves. The device treats insomnia but is not a sedative - instead, the device modulates the brain to produce a restful state that accelerates sleep onset and restores longer periods of sleep.

What does the stimulation feel like?

Many patients do not feel the stimulation at all, while some may feel a mild tingling at the sponge contact sites.

Are there any side effects?

When used cranially to treat insomnia, depression and anxiety, less than 1% of patients report a mild headache upon using the device.

What activities may I do while I use the stimulator?

Resting quietly is best, but one can engage in activities such as reading, watching TV, using the computer, or talking on the phone during a treatment session.

Senior Leadership

Kelly Roman

kellyroman

Chip Fisher

Kelly Roman

Co-Founder & CEO & Director

For the past decade, Kelly Roman has helped lead the fields of neuromodulation product development, regulatory affairs, healthcare marketing and clinical trial strategy. Prior to co-founding Fisher Wallace, Kelly graduated from Harvard and served as an award-winning executive in the digital advertising and SaaS industries. He recently served on the boards of two charter high schools in New York City.

Co-Founder & Chairman & Director

Charles “Chip” Fisher grew up in the electronics business before helping pioneer the neuromodulation industry - his father, Avery Fisher, founded Fisher Radio (later named Fisher Electronics). After graduating from Harvard and serving as a sales executive at IBM, Chip acquired the original intellectual property to the Fisher Wallace Stimulator and is the company’s largest shareholder - and recent TEDx contributor.

Co-Founder & CEO & Director

For the past decade, Kelly Roman has helped lead the fields of neuromodulation product development, regulatory affairs, healthcare marketing and clinical trial strategy. Prior to co-founding Fisher Wallace, Kelly graduated from Harvard and served as an award-winning executive in the digital advertising and SaaS industries. He recently served on the boards of two charter high schools in New York City.

This Reg A+ offering is made available through StartEngine Primary, LLC. It is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. Please review the offering circular before investing.

Copyright © 2021 Fisher Wallace